Details for New Drug Application (NDA): 209815
✉ Email this page to a colleague
NDA 209815 describes CLOTRIMAZOLE, which is a drug marketed by Fougera Pharms, Glenmark Pharms, Taro, P And L, Novitium Pharma, Sciegen Pharms Inc, Teva, Trupharma, Hikma, Padagis Us, Thinq Pharm-cro Pvt, Actavis Mid Atlantic, and Glenmark Speclt, and is included in nineteen NDAs. It is available from twenty-four suppliers. Additional details are available on the CLOTRIMAZOLE profile page.
The generic ingredient in CLOTRIMAZOLE is betamethasone dipropionate; clotrimazole. There are sixty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; clotrimazole profile page.
The generic ingredient in CLOTRIMAZOLE is betamethasone dipropionate; clotrimazole. There are sixty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; clotrimazole profile page.
Summary for 209815
| Tradename: | CLOTRIMAZOLE |
| Applicant: | Novitium Pharma |
| Ingredient: | clotrimazole |
| Patents: | 0 |
Suppliers and Packaging for NDA: 209815
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CLOTRIMAZOLE | clotrimazole | SOLUTION;TOPICAL | 209815 | ANDA | Novitium Pharma LLC | 70954-036 | 70954-036-20 | 1 BOTTLE in 1 CARTON (70954-036-20) / 30 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;TOPICAL | Strength | 1% | ||||
| Approval Date: | Feb 14, 2019 | TE: | AT | RLD: | No | ||||
Complete Access Available with Subscription
